New York University New Drug Application Paper

Based on the information provided below and discussed in class, prepare a 3 – 4 page reportoutlining recommendations for preparation, submission, and maintenance of a New Drug Application(NDA).Background Information:The NDA is the vehicle Sponsors use to propose the FDA approve a drug for sale in the UnitedStates, and the goals of the NDA are to allow FDA personnel reviewing the application to determinewhether the drug has an acceptable risk-benefit profile for the proposed indication and whether thelabeling is appropriate for proper use of the drug. It must allow the FDA to determine whethermanufacturing and controls allow the product to be made reliably and of consistently high quality.NDA submission is a pivotal moment in the transformation of a scientific concept into atherapeutic commodity, and its review marks FDA’s last chance to determine whether a drug is safe andeffective before it can be administered to the general public. Following FDA approval, routine yet veryimportant activities, such as postmarket surveillance and safety reporting, are required to maintain anapproved NDA, and therefore, an approved drug on the market available to patients.Getafix Pharmaceuticals is a small pharmaceutical company developing a compound it hopes tomarket someday for treating Alzheimer’s disease. The company has maintained an effective IND for over10 years, to which over 100 IND amendments containing a variety of documents have been submitted(e.g. nonclinical reports, meeting materials, safety reports, manufacturing changes, clinical studyprotocols and reports). Now, with promising phase II results and two global, parallel phase III clinicalstudies underway, Getafix hopes to submit an NDA to FDA within two years. With limited resources andexpertise, the company has requested your help as a Regulatory Affairs Consultant. Prompt:Outline operational and strategic considerations Getafix should take into account throughoutNDA preparation. Within your plan, provide a brief introduction describing the purpose of the NDA andits review by the FDA. Indicate whether you would recommend a Pre-NDA meeting with FDA, and if so,describe the contents of required meeting material and potential goals of the meeting. Describedocumentation required for initial NDA submission and outline post-approval activities Getafix wouldneed to perform to keep the drug on the market in the United States. Also, consider the possibility of anAdvisory Committee Meeting and outline steps needed to prepare for this during NDA preparation.Justify your recommendations by referencing applicable regulations from 21 CFR and advice from FDAGuidances and ICH Guidelines.